Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-07 17:30 |
Communiqué de presse : ASH : le rilzabrutinib a apporté un bénéfice significati…
|
French | 235.4 KB | ||
| 2024-12-06 07:30 |
Press Release: Availability of the revised financial statements for Sanofi excl…
|
English | 137.6 KB | ||
| 2024-12-06 07:30 |
Communiqué de presse : Mise en ligne des états financiers révisés de Sanofi hor…
|
French | 138.4 KB | ||
| 2024-11-20 14:11 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octob…
|
French | 121.6 KB | ||
| 2024-11-20 14:11 |
Sanofi: Information concerning the total number of voting rights and shares - O…
|
English | 145.6 KB | ||
| 2024-11-18 18:23 |
6-K
|
English | 42.1 KB | ||
| 2024-11-15 07:00 |
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chron…
|
English | 225.9 KB | ||
| 2024-11-15 07:00 |
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent da…
|
French | 227.5 KB | ||
| 2024-11-14 17:42 |
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE…
|
French | 177.7 KB | ||
| 2024-11-14 17:42 |
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transp…
|
English | 186.2 KB | ||
| 2024-11-07 20:49 |
SCHEDULE 13GA
|
English | 12.9 KB | ||
| 2024-11-07 17:35 |
6-K
|
English | 33.1 KB | ||
| 2024-11-06 07:00 |
Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE …
|
French | 256.0 KB | ||
| 2024-11-06 07:00 |
Press Release: Dupixent approved in the EU as the first and only medicine for y…
|
English | 240.6 KB | ||
| 2024-10-31 11:56 |
6-K
|
English | 39.4 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
